A Study of Intratumoural/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Official Title

A Phase 1/1b, Open-label Clinical Study of Intratumoural/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies

Summary:

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and V938 shedding in participants with advanced/metastatic or recurrent malignancies who receive V938 in Combination with Pembrolizumab (MK-3475). The primary objective is to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (PRP2D) of V938 administered in combination with pembrolizumab.

Trial Description

Primary Outcome:

  • Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
  • Number of Participants Who Experience ≥1 Adverse Event (AE)
  • Number of Participants Who Discontinue Study Drug Due to an Adverse Event (AE)
Secondary Outcome:
  • Objective Response Rate (ORR)
  • Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) for V938 Ribonucleic Acid (RNA) in Plasma
  • Maximum Concentration (Cmax) of V938 Ribonucleic Acid (RNA) Reached in Plasma
  • V938 Excretion: Polymerase Chain Reaction (PCR)
  • V938 Excretion: Infectivity

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society